Clinical trials of deep vein thrombosis prophylaxis in medical patients

Clinical Cornerstone

Volumn 7, Issue 4, 2005, Pages 16-22

  Ageno, Walter ^a   Turpie, Alexander G G ^b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; POLYSACCHARIDE;

ARTICLE; AUTOPSY; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; COMPRESSION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ECHOGRAPHY; EVIDENCE BASED MEDICINE; HEART FAILURE; HOSPITAL PATIENT; HUMAN; IMMOBILIZATION; INFECTION; INFLAMMATION; LUNG EMBOLISM; MEDICAL AUDIT; MORBIDITY; MORTALITY; PHLEBOGRAPHY; PRACTICE GUIDELINE; RESPIRATORY FAILURE; SURGICAL PATIENT; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; AGED; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOEMBOLISM; VEIN THROMBOSIS;

AGED; ANTICOAGULANTS; DALTEPARIN; ENOXAPARIN; HUMANS; MIDDLE AGED; POLYSACCHARIDES; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33745266404     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(05)80099-7     Document Type: Article

References (34)

1. Sandler D.A., and Martin I.F. Autopsy proven pulmonary embolism in hospital patients: Are we detecting enough deep vein thrombosis?. J R Soc Med 82 (1989) 203-205
2. Goldhaber S.Z., Savage D.D., Garrison R.J., et al. Risk factors for pulmonary embolism: The Framingham study. Am J Med 74 (1983) 1023-1028
3. Anderson F.A., Wheeler H.B., Goldberg R.J., et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 151 (1991) 933-938
4. Lindblad B., Stemby N.H., and Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. Br Med J 302 (1991) 709-711
5. Leizorovicz A., and Mismetti P. Preventing venous thromboembolism in medical patients. Circulation 110 Suppl IV (2004) IV13-IV19
6. (Suppl). Bouthier J. The venous thrombotic risk in nonsurgical patients. Drugs 52 (1996) 16-29
7. Goldhaber S.Z., Dunn K., and MacDougall R.C. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest 118 (2000) 1680-1684
8. Monreal M., Kakkar A.K., Caprini J.A., et al., RIETE Investigators. The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE Registry. J Thromb Haemost 2 (2004) 1892-1898
9. Samama M.M., Cohen A.T., Darmon J.Y., et al., Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 341 (1999) 793-800
10. Leizorovicz A., Cohen A.T., Turpie A.G., et al., PREVENT Medical Thromboprophylaxis Study. Randomized, placebo-controlled trial of dalteparin for the pre vention of venous thromboembolism in acutely ill medical patients. Circulation 110 (2004) 874-879
11. Cohen A.T., Davidson B., Gallus A.S., et al. Fondaparinux for the prevention of VTE in acutely ill medical patients. Artemis Study. Blood 102 (2003) 15a
12. Geerts W.H., Pineo G.F., Heir J.A., et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 338S-400S
13. Ageno W., Squizzato A., Ambrosini F., et al. Thrombosis prophylaxis in medical patients: A retrospective review of clinical practice patterns. Haematologica 87 (2002) 746-750
14. Abstract. Anderson Jr. F.A., Tapson V.F., Decousus H., et al. IMPROVE, a multinational observational cohort study of practices in prevention of venous thromboembolism in acutely ill medical patients: A comparison with clinical study patient populations. Blood 102 (2003) 1146
15. Rahim S.A., Panju A., Pai M., and Ginsberg J. Venous thromboembolism prophylaxis in medical inpatients: A retrospective chart review. Thromb Res 111 (2003) 215-219
16. Belch J.J., Lowe G.D., Ward A.G., et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 26 (1981) 115-117
17. Halkin H., Goldberg J., Modan M., and Modan B. Reduction in mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 96 (1982) 561-565
18. Cade I.F. High risk of the critically ill for venous thromboembolism. Crit Care Med 10 (1982) 448-450
19. Gardlund B., and Heparin Prophylaxis Study Group. Randomised, controlled trial of low dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet 347 (1996) 1357-1361
20. (Munich). Poniewierski M., Barthels M., Kuhn M., and Poliwoda H. Effectiveness of low molecular weight heparin (Fragmin) in the prevention of thromboembolism in internal medicine patients. A randomized double-blind study. March 31. Med Klin 83 7 (1988) 241-245
21. (Munich). Poniewierski M., Barthels M., Kuhn M., and Poliwoda H. Effectiveness of low molecular weight heparin (Fragmin) in the prevention of thromboembolism in internal medicine patients. A randomized double-blind study. March 31. Med Klin 83 7 (1988) 278
22. Harenberg J., Kaltenbach B., Martin U., et al. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep vein thrombosis in medical patients. Thromb Res 59 (1990) 639-650
23. Forette B., and Wolmark Y. Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Study of tolerance. Press Med 24 (1995) 567-571
24. Harenberg J., Roebruck P., and Heene D.L. Subcutaneous low molecular weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine (HESIM) Group. Haemostasts 26 (1996) 127-139
25. Manciet G., Vergnes C., Vaissié J.J., and Boisseau M.R. Study of the efficacy and tolerance of Fraxipauni administered long term to older subjects, randomized blended study. In: Bounameaux H., Samama M.M., and Ten Cate J.W. (Eds). Fraxiparine, 2nd International Symposium. Recent pharmacological and clinical data (1990), Schattauer, Stuttgart, NY 55-59
26. Bergmann J.F., and Caulin C. Heparin prophylaxis in bedridden patients. Lancet 348 (1996) 205-206
27. Dahan R., Houlbert D., Caulin C., et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: A randomized double-blind trial. Haemostasis 16 (1986) 159-164
28. Lechler E., Schramm W., and Flosbach C.W. The venous thrombotic risk in non-surgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (Enoxaparin). Haemostasis 26 Suppl 2 (1996) 49-56
29. Bergmann J.F., and Neuhart E. A multicenter randomized doubleblind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic dis ease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost 76 (1996) 529-534
30. Kleber F.X., Witt C., Vogel G., et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 145 (2003) 614-621
31. Mismetti P., Laporte-Simitsidis S., Tardy B., et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low molecular weight heparins: A meta analysis of randomised clinical trials. Thromb Haemost 83 (2000) 14-19
32. Alikhan R., Cohen A.T., Combe S., et al. Prevention of venous thromboembolism in medical patients with enoxaparin: A subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 14 (2003) 341-346
33. Alikhan R., Cohen A.T., Combe S., et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: Analysis of the MEDENOX Study. Arch Intern Med 164 (2004) 963-968
34. Kucher N., Leizorovicz A., Vaitkus P.T., et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: A subgroup analysis of the PREVENT trial. Arch Intern Med 165 (2005) 341-345